POSA61 Incremental Cost per Relapse Avoided of Ozanimod Compared with First-Line Disease-Modifying Therapies for Relapsing Forms of Multiple Sclerosis
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.206
https://www.valueinhealthjournal.com/article/S1098-3015(21)02001-5/fulltext
Title :
POSA61 Incremental Cost per Relapse Avoided of Ozanimod Compared with First-Line Disease-Modifying Therapies for Relapsing Forms of Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02001-5&doi=10.1016/j.jval.2021.11.206
First page :
Section Title :
Open access? :
No
Section Order :
10980